An overview of drug development for metastatic breast cancer

British Journal of Nursing

Volumn 21, Issue 4 SUPPL., 2012, Pages

  Stebbing, Justin ^a   Ellis, Paul ^b  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Breast cancer; Drugs; Metastatic; Research; Targets

Indexed keywords

EID: 84858657974     PISSN: 09660461     EISSN: None     Source Type: Journal    
DOI: 10.12968/bjon.2012.21.sup4.s18     Document Type: Review

References (26)

1. Adjuvant! Online (2003) Decision making tools for health care professionals. http://tinyurl. com/73u3cyk (accessed 6 February 2012)
2. Ahamed E, Mauri FA, Pakter G, Lim A, Stebbing J (2009) Trastuzumab: unusual responses and toxicities. Future Oncol 5(6): 779-84
3. Dontu G, Liu S, Wicha MS (2005) Stem cells in mammary development and carcinogenesis: implications for prevention and treatment. Stem Cell Rev 1(3): 207-13
4. Giamas G, Stebbing J, Vorgias CE, Knippschild U (2007) Protein kinases as targets for cancer treatment. Pharmacogenomics 8(8): 1005-16 (Pubitemid 47430443)
5. Giamas G, Man YL, Hirner H et al (2011a) Kinases as targets in the treatment of solid tumors. Cell Signal 22(7): 984-1002. Epub 2010.
6. Giamas G, Filipovic A, Jacob J et al (2011b) Kinome screening for regulators of the estrogen receptor identifies LMTK3 as a new therapeutic target in breast cancer. Nat Med 17(6): 715-9. Epub.
7. Hahn WC, Weinberg RA (2002) Modelling the molecular circuitry of cancer. Nat Rev Cancer 2(5): 331-41 (Pubitemid 37328946)
8. Hajage D, de Rycke Y, Bollet M et al (2011) External validation of Adjuvant! Online breast cancer prognosis tool. Prioritising recommendations for improvement. PLoS One 6(11): e27446. Epub.
9. Heudel PE, Tredan O, Ray-Coquard I, Treilleux I, Guastalla JP, Bachelot T (2011) [Antihormonal therapy in breast cancer and mTOR inhibitors]. Bull Cancer98(12):1431-7
10. Hortobagyi GN (2005) Trastuzumab in the treatment of breast cancer. Engl J Med 353(16): 1734-6 (Pubitemid 41464714)
11. Hurvitz S, Dirix L, Kocsis J et al (2011) Transtuzumab emtansine (T-DM1) vs trastuzumab plus docetaxel (H+T) in previously untreated HER-2 positive metastatic breast cancer (MBC): primary results of a randomized, multicenter, open-label phase II study (TDM4450g/BO21976). Abstract 5001. European Multidisciplinary Cancer Congress, Stockholm
12. Jiao LR, Apostolopoulos C, Jacob J et al (2009) Unique localization of circulating tumor cells in patients with hepatic metastases. J Clin Oncol 27(36): 6160-5. Epub.
13. LoRusso PM, Weiss D, Guardino E, Girish S, Sliwkowski MX (2011) Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer. Clin Cancer Res 17(20): 6437-47
14. Lyons JG, Lobo E, Martorana AM, Myerscough MR (2008) Clonal diversity in carcinomas: its implications for tumour progression and the contribution made to it by epithelialmesenchymal transitions. Clin Exp Metastasis 25(6): 665-77. Epub 2007.
15. Mathew J, Perez EA (2011) Trastuzumab emtansine in human epidermal growth factor receptor 2-positive breast cancer: a review. Curr Opin Oncol 23(6): 594-600
16. Miles DW, Chan A, Dirix LY et al (2010) Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 28(20):3239-47. Epub.
17. Ogilvie D, Craig P, Griffin S, Macintyre S, Wareham NJ (2009) A translational framework for public health research. BMC Public Health 9: 116
18. O'Shaughnessy J, Osborne C, Pippen JE et al (2011) Iniparib plus chemotherapy in metastatic triple-negative breast cancer. Engl J Med 364(3): 205-14. Epub.
19. Polyak K (2011) Heterogeneity in breast cancer. J Clin Invest 121(10):3786-8
20. Saini KS, Azim HA Jr, Metzger-Filho O et al (2011) Beyond trastuzumab: new treatment options for HER2-positive breast cancer. Breast 20(3Suppl): S20-7
21. Stebbing J, Jiao LR (2009) Circulating tumour cells as more than prognostic markers. Lancet Oncol 10(12): 1138-9. Epub.
22. Stebbing J, Ngan S (2010) Breast cancer (metastatic). Clin Evid (Online). pii: 0811
23. Stebbing J, Ellis P, Tutt A (2010) PARP inhibitors in BRCA1-/BRCA2-associated and triple-negative breast cancers. Future Oncol 6(4):485-6
24. Stebbing J, Filipovic A, Giamas G (2011a) Lemur tyrosine kinase-3 (LMTK3) in cancer and evolution. Oncotarget. 2(6): 428-9
25. Stebbing J, Filipovic A, Ellis IO et al (2011b) LMTK3 expression in breast cancer: association with tumor phenotype and clinical outcome. Breast Cancer Res Treat June 14 [Epub ahead of print]
26. Tutt AN, Lord CJ, McCabe et al (2005) Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer. Cold Spring Harb Symp Quant Biol 70: 139-48 (Pubitemid 44124865)